2022 Fiscal Year Final Research Report
Seeds research including Chromogranin B for elucidation of pathophysiology of Parkinson's syndrome
| Project/Area Number |
19K07939
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52010:General internal medicine-related
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | 神経学 / 老年医学 / 神経変性疾患 / 分子生物学 / 進行性核上性麻痺 / 大脳皮質基底核変性症 / パーキンソン症候群 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
Parkinson's syndrome (PS), including Parkinson's disease, is a progressive neurodegenerative disease of unknown cause, and there is still no effective treatment. Differential diagnosis of PS is often difficult clinically. Proteomics analyzes of cerebrospinal fluid revealed molecules such as chromogranin B (CHGB) and amyloid precursor protein (APP) as candidate biomarkers for progressive supranuclear palsy (PSP), a type of PS. We have also obtained PSP-specific microRNA candidates by microRNA array analysis. Validation studies were conducted on these biomarker candidates, and it was suggested that these biomarkers could serve as seeds for the promotion of clinical research on PS.
|
| Free Research Field |
脳神経内科
|
| Academic Significance and Societal Importance of the Research Achievements |
PSは原因不明で有効な治療法はなく，各疾患の関連や相違など疾患分類や位置づけについてこれまでにも多くの議論がなされてきているが，未だ明らかにはなっていない．PSでは明確なバイオマーカーは確立されておらず，臨床症状，形態画像，薬剤への反応性などから臨床診断するしかなく，病初期には臨床診断が困難な場合が少なくない．バイオマーカーの確立は，早期臨床診断，病態解明，治療戦略開発にむけたシーズになることが期待される．
|
